Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03149315 · ClinicalTrials.gov registry record · Phase 2
Inhibition of Anaphylaxis by Ibrutinib
A Phase 2 study, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03149315 is a Phase 2 study that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 6 participants.
The verdict
NCT03149315, a Phase 2 study, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a phase II open label study on the use of Ibrutinib on the inhibition of food-induced anaphylaxis in adults with food allergy. Ibrutinib (brand name Imbruvica) is currently FDA approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom's macroglobulineia (WM). We propose to administer this approved drug to adults with food allergy to inhibit food allergy responses.
Interventions
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-04-10 |
| Est. Completion | 2018-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03149315
The ClinicalTrials.gov registry entry for NCT03149315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrutinib is the first listed.
NCT03149315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03149315 about?
NCT03149315 is a clinical study titled "Inhibition of Anaphylaxis by Ibrutinib". This is a phase II open label study on the use of Ibrutinib on the inhibition of food-induced anaphylaxis in adults with food allergy. Ibrutinib (brand name Imbruvica) is currently FDA approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom's mac...
What is the current status of trial NCT03149315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-04-10. Estimated completion is 2018-11-14.
What interventions are being tested in trial NCT03149315?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03149315?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.